Yang, Seung-Hoon Kim, Jiyoon Lee, Michael Jisoo Kim, YoungSoo 2024-01-20T06:01:00Z 2024-01-20T06:01:00Z 2022-01-10 2015-10-27 2045-2322 https://pubs.kist.re.kr/handle/201004/124868 The blood-based diagnosis has a potential to provide an alternative approach for easy diagnosis of Alzheimer's disease (AD) with less invasiveness and low-cost. However, present blood-based AD diagnosis mainly focuses on measuring the plasma A beta level because no other biomarkers are found to possess evident transport mechanisms to pass the blood-brain barrier. In order to avoid diagnosing non-demented individuals with A beta abnormality, finding additional biomarkers to supplement plasma A beta is essential. In this study, we introduce potential neurodegenerative biomarkers for blood-based diagnosis. We observed severe splenomegaly and structural destruction in the spleen with significantly decreased B lymphocytes in senile APP(swe), PS1(M146V) and Tau(P301L) transgenic mice. We also found that inflammatory cytokines associated with splenic dysfunction were altered in the plasma of these mice. These findings suggest potential involvement of the splenic dysfunction in AD and the importance of biomarker level alterations in the plasma as putative diagnostic targets for AD. English NATURE PUBLISHING GROUP ALZHEIMERS-DISEASE NEUROPSYCHIATRIC SYMPTOMS COGNITIVE IMPAIRMENT A-BETA TAU DIAGNOSIS MILD PET NEUROPATHOLOGY BIOMARKERS Abnormalities of plasma cytokines and spleen in senile APP/PS1/Tau transgenic mouse model Article 10.1038/srep15703 1 SCIENTIFIC REPORTS, v.5 SCIENTIFIC REPORTS 5 scie scopus 000363448400001 2-s2.0-84945944257 Multidisciplinary Sciences Science & Technology - Other Topics Article ALZHEIMERS-DISEASE NEUROPSYCHIATRIC SYMPTOMS COGNITIVE IMPAIRMENT A-BETA TAU DIAGNOSIS MILD PET NEUROPATHOLOGY BIOMARKERS Alzheimer dementia blood 알츠하이머 치매 혈액진단